Home LiteratureArticle Details
PMID: 31740982 Published · ppublish ger Journal Article Comment

[Durvalumab after radiochemotherapy for locally advanced unresectable NSCLC-a breakthrough].

Durvalumab nach Radiochemotherapie beim lokal fortgeschrittenen inoperablen NSCLC – ein Sprung nach vorn.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] ·Vol. 196 ·No. 1 ·2020-00-00 ·Pages 95-97

Guckenberger M

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal Carcinoma, Non-Small-Cell Lung Chemoradiotherapy Humans Lung Neoplasms
Chemicals
Antibodies, Monoclonal durvalumab
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Guckenberger Matthias
Department of Radiation Oncology, Competence Center Palliative Care, University Hospital Zurich (USZ), Rämistrasse 100, 8091, Zürich, Schweiz. Matthias.Guckenberger@usz.ch.
References (18)
18 references, click to expand
  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    N Engl J Med. 2018 Jun 14;378(24):2288-2301 PMID: 29863955
  2. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Lancet. 2015 Sep 12;386(9998):1049-56 PMID: 26275735
  3. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    J Clin Oncol. 2015 Dec 10;33(35):4194-201 PMID: 26527789
  4. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21 PMID: 28881918
  5. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2016 Nov 10;375(19):1823-1833 PMID: 27718847
  6. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019 Feb 1;30(2):161-165 PMID: 30624547
  7. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
    Nat Commun. 2017 Jun 09;8:15618 PMID: 28598415
  8. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
    N Engl J Med. 2018 Dec 13;379(24):2342-2350 PMID: 30280658
  9. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
    Clin Cancer Res. 2018 Oct 15;24(20):5058-5071 PMID: 29898992
  10. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Nature. 2015 Apr 16;520(7547):373-7 PMID: 25754329
  11. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
    J Clin Oncol. 2010 May 1;28(13):2181-90 PMID: 20351327
  12. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer.
    Radiother Oncol. 2017 Jul;124(1):1-10 PMID: 28666551
  13. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Lancet Oncol. 2015 Feb;16(2):187-99 PMID: 25601342
  14. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Lung Cancer. 2019 Jul;133:83-87 PMID: 31200833
  15. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
    Radiother Oncol. 2016 Aug;120(2):185-94 PMID: 27495145
  16. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Nov 16;377(20):1919-1929 PMID: 28885881
  17. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
    N Engl J Med. 2004 Jan 22;350(4):351-60 PMID: 14736927
  18. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
    Cancer Res. 2014 Oct 1;74(19):5458-68 PMID: 25274032
Article Info
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Abbr.
Strahlenther Onkol
ISSN
1439-099X
DOI
10.1007/s00066-019-01545-3
Email
matthias.guckenberger@usz.ch
Published
2020-00-00
Pages
95-97
Language
ger
Region
Germany
NLM ID
8603469
Subset
IM
Corrections
CommentOn
PMID: 30280658
External Links
PubMed source DOI: 10.1007/s00066-019-01545-3 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2